Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$12.52

0.25 (2.04%)

, ABBV

AbbVie

$97.29

-0.73 (-0.74%)

07:51
08/29/18
08/29
07:51
08/29/18
07:51

AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.

OBSV

ObsEva

$12.52

0.25 (2.04%)

ABBV

AbbVie

$97.29

-0.73 (-0.74%)

  • 04

    Sep

  • 05

    Sep

  • 12

    Sep

OBSV ObsEva
$12.52

0.25 (2.04%)

08/07/18
08/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) reinstated with an Overweight at Barclays. 2. ObsEva (OBSV) initiated with an Outperform at Wedbush. 3. Deciphera (DCPH) initiated with a Buy at Canaccord. 4. Alliance Data (ADS) assumed with a Buy at Jefferies. 5. Hermes (HESAY) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $44
HCWC
Buy
ObsEva price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 "appears to be comfortably above this level," Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva's linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
08/15/18
LEER
08/15/18
INITIATION
Target $25
LEER
Outperform
ObsEva resumed with an Outperform at Leerink
Leerink analyst Ami Fadia resumed coverage of ObsEva with an Outperform rating and $25 price target. The analyst believes that at current levels the stock does not fully reflect the commercial potential of its lead product linzagolix, which she believes can reach over $1B in peak sales, its additional women's health pipeline, and its more than $100M cash balance that can fund operation into 1H20, by which time she expects to get positive UF Phase 3 data readout for linzagolix.
08/15/18
08/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with an Outperform at William Blair. 2. ObsEva (OBSV) resumed with an Outperform at Leerink. 3. Idera Pharmaceuticals (IDRA) resumed with an Overweight at JPMorgan. 4. DTE Energy (DTE) initiated with an Equal Weight at Barclays. 5. Tellurian (TELL) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ABBV AbbVie
$97.29

-0.73 (-0.74%)

07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $100
PIPR
Neutral
Worries about AbbVie's Humira keep Piper Jaffray on sidelines
Piper Jaffray analyst Christopher Raymond said he finds "little to quibble with" in AbbVie's Q2 report, but also noted that while its FY18 EPS guidance was raised, its revenue guidance actually came down slightly. Raymond, who continues to worry that consensus does not fully factor in the extent of ex-U.S. Humira pressure or the further pressure from co-pay accumulator programs in the U.S., prefers to stay on the sidelines and keeps a Neutral rating on the shares. He also lowered his price target on AbbVie to $100 from $105.
08/22/18
PIPR
08/22/18
NO CHANGE
Target $130
PIPR
Overweight
AbbVie decision suggests positive Argenx data, says Piper Jaffray
AbbVie's (ABBV) decision to exercise an exclusive option to license Argenx's (ARGX) anti-GARP antibody, ARGX-115, suggests positive preclinical data, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst looks for investigational new drug application filing plans this year. He reiterates an Overweight rating on shares of Argenx with a $130 price target.

TODAY'S FREE FLY STORIES

ALGT

Allegiant Travel

$124.89

-1.45 (-1.15%)

18:37
12/10/18
12/10
18:37
12/10/18
18:37
Hot Stocks
Allegiant reports November total systems traffic up 10.1% »

Reports total systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$108.55

2.85 (2.70%)

18:27
12/10/18
12/10
18:27
12/10/18
18:27
Periodicals
Splunk CEO says customers can now talk via voice-enabled assistants, CNBC says »

Splunk president and CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 19

    Dec

  • 20

    Dec

  • 09

    Jan

EFC

Ellington Financial

$15.57

0.01 (0.06%)

18:22
12/10/18
12/10
18:22
12/10/18
18:22
Hot Stocks
Ellington Financial reports book value per share of $19.37 as of Nov. 30th »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

18:22
12/10/18
12/10
18:22
12/10/18
18:22
Periodicals
New 'Smash Bros.' fastest selling Switch game so far, Gamesindustry.biz says »

Nintendo's latest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

, GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

18:15
12/10/18
12/10
18:15
12/10/18
18:15
Periodicals
Google CEO supports privacy law, denies political bias, Bloomberg says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

APTI

Apptio

$37.86

-0.17 (-0.45%)

18:13
12/10/18
12/10
18:13
12/10/18
18:13
Downgrade
Apptio rating change  »

Apptio downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

$8.56

0.21 (2.52%)

18:00
12/10/18
12/10
18:00
12/10/18
18:00
Hot Stocks
Newmark CEO Barry Gosin buys over $2.6M in company shares »

Newmark CEO Barry Gosin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVTC

Evertec

$26.83

-0.365 (-1.34%)

17:52
12/10/18
12/10
17:52
12/10/18
17:52
Hot Stocks
Evertec EVP Ramirez sells 44,378 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

ALTM

Altus Midstream Company

$8.50

0.6 (7.59%)

, APA

Apache

$31.27

-1.74 (-5.27%)

17:46
12/10/18
12/10
17:46
12/10/18
17:46
Hot Stocks
Apache reports 13.4% stake in Altus Midstream Company »

This stake allows for…

ALTM

Altus Midstream Company

$8.50

0.6 (7.59%)

APA

Apache

$31.27

-1.74 (-5.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$177.13

0.03 (0.02%)

, IBM

IBM

$121.13

1.77 (1.48%)

17:45
12/10/18
12/10
17:45
12/10/18
17:45
Hot Stocks
Red Hat sets January 16 special meeting for vote on IBM merger »

Red Hat, Inc. (RHT)…

RHT

Red Hat

$177.13

0.03 (0.02%)

IBM

IBM

$121.13

1.77 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

YMAB

Y-mAbs Therapeutics

$22.17

-0.36 (-1.60%)

17:42
12/10/18
12/10
17:42
12/10/18
17:42
Hot Stocks
Y-mAbs Therapeutics humanized bispecific GD2 antibody IND receives FDA clearance »

Y-mAbs Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$117.68

-0.39 (-0.33%)

17:39
12/10/18
12/10
17:39
12/10/18
17:39
Hot Stocks
SPDR Gold Shares holdings rise to 760.32MT from 759.73MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAEX

SAExploration

$3.33

-0.11 (-3.20%)

17:35
12/10/18
12/10
17:35
12/10/18
17:35
Syndicate
SAExploration files to sell common stock for holders »

SAExploration filed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$40.47

-0.25 (-0.61%)

17:27
12/10/18
12/10
17:27
12/10/18
17:27
Syndicate
Breaking Syndicate news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCC

Wesco

$49.28

-0.675 (-1.35%)

17:26
12/10/18
12/10
17:26
12/10/18
17:26
Initiation
Wesco initiated  »

Wesco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MTEM

Molecular Templates

$4.30

-0.08 (-1.83%)

17:25
12/10/18
12/10
17:25
12/10/18
17:25
Initiation
Molecular Templates initiated  »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

COHR

Coherent

$119.34

-0.28 (-0.23%)

17:23
12/10/18
12/10
17:23
12/10/18
17:23
Initiation
Coherent initiated  »

Coherent initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAMP

CalAmp

$17.02

-0.23 (-1.33%)

17:22
12/10/18
12/10
17:22
12/10/18
17:22
Hot Stocks
CalAmp announces $20M stock repurchase program »

CalAmp announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CR

Crane

$78.23

-0.99 (-1.25%)

17:22
12/10/18
12/10
17:22
12/10/18
17:22
Initiation
Crane initiated  »

Crane initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

$1.31

-0.03 (-2.24%)

17:22
12/10/18
12/10
17:22
12/10/18
17:22
Initiation
BioTime initiated  »

BioTime initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVAX

Novavax

$2.14

0.09 (4.39%)

17:20
12/10/18
12/10
17:20
12/10/18
17:20
Initiation
Novavax initiated  »

Novavax initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$207.84

-3.275 (-1.55%)

17:19
12/10/18
12/10
17:19
12/10/18
17:19
Initiation
Lennox initiated  »

Lennox initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FCAU

Fiat Chrysler

$15.33

(0.00%)

17:17
12/10/18
12/10
17:17
12/10/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Fiat Chrysler »

Tiger Global reports 5.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$169.61

1.24 (0.74%)

17:15
12/10/18
12/10
17:15
12/10/18
17:15
Recommendations
Apple analyst commentary  »

Apple pullback is a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$121.93

-0.69 (-0.56%)

17:14
12/10/18
12/10
17:14
12/10/18
17:14
Initiation
Stanley Black & Decker initiated  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.